Australian MDMA, psychedelic mushroom studies to move to recruitment phase
January 13 2021 – Team MindFuel
This year, four Australian institutions will start recruiting for separate research into using psilocybin and MDMA for PTSD, addiction, depression and anxiety.
Edith Cowan and Monash universities will begin separate trials into the potential for MDMA to treat post-traumatic stress disorder.
St Vincent's Hospital Sydney will examine the impact of psilocybin on preventing methamphetamine relapse, Monash will study its effect on generalized anxiety disorder and the University of Melbourne will look at its potential to treat depression.
Researchers emphasize the importance of ensuring that Australia can build on previous work done elsewhere, and that they're ready to roll out treatment when possible. "We need to demonstrate that we have the people and infrastructure to do it safely," said Dr Stephen Bright of Edith Cowan University.
Edith Cowan and Monash universities will begin separate trials into the potential for MDMA to treat post-traumatic stress disorder.
St Vincent's Hospital Sydney will examine the impact of psilocybin on preventing methamphetamine relapse, Monash will study its effect on generalized anxiety disorder and the University of Melbourne will look at its potential to treat depression.
Researchers emphasize the importance of ensuring that Australia can build on previous work done elsewhere, and that they're ready to roll out treatment when possible. "We need to demonstrate that we have the people and infrastructure to do it safely," said Dr Stephen Bright of Edith Cowan University.
Sources: The Canberra Times, The Beckley Foundation, Entheogenesis Australia.
0 comments